Updated from 3:12 p.m. EST

Johnson & Johnson's ( JNJ) shares closed to the downside Tuesday amid a weak forecast from the company and a down day overall for the U.S. stock market.

The New Jersey-based drug and consumer-products giant predicted earnings for 2009 of $4.45 to $4.55 a share, which excludes the impact of certain items, but includes a reduction of 3 cents to 5 cents from the pending acquisition of Mentor ( MNT). On average, analysts surveyed by Thomson Reuters are calling for $4.61.

J&J's outlook came as the company reported fourth-quarter earnings of $2.7 billion, or 97 cents a share. Before items, the company would have earned 94 cents, 2 cents better than expectations. In the same quarter last year, J&J had a profit of $2.4 billion, or 82 cents a share.

Worldwide sales in the quarter fell 4.9% year over year to $15.2 billion, a decline that was primarily attributable to unfavorable exchange rates, and missed Wall Street's $15.9 billion consensus estimate. Sales rose 4.3% for the full year to $63.7 billion, and adjusted earnings were $4.55 a share.

Shares of J&J closed down 69 cents, or 1.2%, to $56.75, after at one point being one of only four stocks in the Dow Jones Industrial Average that was up for the day, along with Merck ( MRK), AT&T ( T) and Verizon ( VZ).

J&J peers Pfizer ( PFE) and Procter & Gamble ( PG) were slightly lower.
This article was written by a staff member of TheStreet.com.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Some of Trump's NFL Owner Friends Side With Players in Dispute With President

The Best Companies for Women

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'